Blockchain

Sui Builders Now to Run on AWS Blockchain Node Runners

on

    More in Blockchain:

    Grand Cayman, Cayman Islands, July 23rd, 2024, Chainwire

     

    Sui joins an exclusive list of AWS-integrated blockchains

    Sui Foundation, the organization dedicated to the advancement and adoption of the layer 1 blockchain of the same name, today announced the integration of Amazon Web Service’s (AWS) Blockchain Node Runners on Sui, providing developers with a self-managed node deployment solution.

    Through this integration, builders on Sui will be able to easily set up and deploy Sui full nodes within the AWS environment, benefitting from the high availability, scalability, and reliability of AWS’s robust cloud infrastructure. AWS Blockchain Node Runners simplifies the process of running blockchain nodes, allowing users to easily deploy, scale, manage, and monitor secure blockchain nodes. As of today, Navi, a leading liquidity protocol, will be engaged as a Node Runner user to deploy full nodes on Sui.

    Kathryn Van Nuys, Global Head of Startups in Specialized Segments at AWS, said, “AWS Blockchain Node Runners was designed to support builders at all stages of the application lifecycle, offering blueprints to meet specific requirements, from enhanced security and compliance to ease of deployment and monitoring. We are excited to bring these and other features to empower developers to deploy and manage Sui nodes on the AWS cloud.”

    Node Runners offers several key technical advantages for deploying blockchain nodes. It provides validated, best-practice deployment templates for scalable node operations across multiple geographies. High availability is ensured through multi-node deployment options across different availability zones. The deployment code is fully open-source and available on GitHub, allowing users to review it before deployment. Integrated with the AWS Well-Architected Framework, Node Runners helps organizations build secure, high-performing, resilient, and efficient node infrastructures. Full nodes on Sui validate on-chain activities such as transactions, checkpoints, and epoch changes, as well as store the stake and history to better service client queries. By offloading query servicing from validator nodes, validators are able to focus on transaction processing and updates to the nodes when new transactions are completed.

    Navi, a leading liquidity on Sui, is one of the first users to engage with Node Runners on Sui, and have deployed their first node via AWS’s service as of today.

    As part of AWS and Sui Foundation’s commitment to empowering Sui builders, developers and startups who utilize AWS Blockchain Node Runners or are building on Sui may be eligible for up to $5,000 in Activate credits. Sui Foundation has also joined the AWS Web3 Provider program, which offers access to tools, resources, content, and credits to Sui developers

    Henrik Johansson, Global Head of Community at Sui Foundation, said, “The integration of AWS Node Runners on Sui marks a pivotal advancement to enhancing blockchain infrastructure. Sui nodes are fundamental to the operation and accessibility of Sui. This integration with AWS not only provides developers with more tools to simplify node deployment but also financial support to utilize and develop on AWS.”

    For more information on utilizing AWS Blockchain Node Runners on Sui, users can visit https://aws-samples.github.io/aws-blockchain-node-runners/docs/Blueprints/Sui.

     

    Contact

    Sui Foundation
    [email protected]

    PostAd_coinrule_banner728x90

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    *

    Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

    2024-10-02T11:08:00Z

    PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

    Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

    Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

    • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
    • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
    • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

    Keiretsu Forum: A Global Leader in Early-Stage Innovation

    Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

    Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

    "Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

    Event Details

    • Date: October 31, 2024
    • Time: 8:00 AM – 6:00 PM EDT
    • Location: Convene City View, 30 S 17th St, Philadelphia, PA

    Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

    About Keiretsu Forum :

    Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

    The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

    About Dr. Martin Gershon

    Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

    Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

    For media inquiries, please contact:

    Cindi Sutera
    AMS Communications
    [email protected]
    610-613-2773


    GlobeNewsWire News

    Recent Comments